Key Takeaways
- • Private equity healthcare deal value reached an estimated record $191 billion in 2025, but the figure masks sharp bifurcation, with capital concentrating in large-cap carve-outs, upper-tier sponsor-to-sponsor recapitalisations and enterprise healthcare IT while mid-market provider roll-ups face compressed multiples and liquidity constraints.
- • The traditional physician practice management roll-up model, built on multiple arbitrage and 6.0x to 8.0x leverage, has broken down under rising interest rates, physician attrition and failed integration, with Chapter 11 filings including CareMax and Canoe Health cited as examples.
- • Federal antitrust agencies now examine serial acquisitions under Guideline 8 of the updated Horizontal Merger Guidelines, with FTC v. U.S. Anesthesia Partners showing that small cumulative acquisitions can violate Section 7 of the Clayton Act.
- • More than 35 states have enacted or expanded transaction review laws requiring advance notice, with California, Oregon, Massachusetts, Washington and New York imposing notice periods of 30 to 180 days and, in some cases, binding operating conditions.
- • CMS disclosure rules requiring ownership reporting at 5% equity thresholds and CMS-HCC Version 28 risk-adjustment changes have compressed margins for Medicare Advantage-focused private equity platforms.
Summary
Private equity's healthcare investment model is undergoing its most significant structural realignment in more than two decades, according to a Nelson Advisors analysis published on healthcare.digital. The historical playbook, which relied on low-cost leverage, fragmented clinical practice roll-ups, valuation multiple arbitrage and aggressive billing optimisation, has been challenged by federal antitrust enforcement, a growing patchwork of state transaction review laws and reductions in Medicare Advantage risk-adjustment reimbursement. The report also notes that enterprise artificial intelligence is creating both productivity gains and pressure on legacy software architectures.
Headline global healthcare private equity deal value rose sharply in 2025 to an estimated record of $191 billion. The analysis argues that this aggregate figure obscures severe bifurcation. Capital has concentrated in large-cap corporate carve-outs, upper-tier sponsor-to-sponsor recapitalisations and healthcare information technology, while mid-market provider practice roll-ups face compressed multiples, longer holding periods and liquidity constraints. Institutional sponsors are responding with stricter underwriting standards focused on market resilience, regulatory insulation and verified organic efficiency.
The analysis attributes the breakdown of the physician practice management roll-up model to several factors. Platforms relied on multiple arbitrage and debt-financed growth, with floating-rate leverage of 6.0x to 8.0x EBITDA underwritten during the zero-interest-rate period. As benchmark rates rose, debt service consumed free cash flow. Physician attrition, driven by higher throughput targets and reduced administrative support, eroded clinical capacity, while many platforms failed to integrate operations, retaining disparate electronic health records and billing practices. The report cites Chapter 11 filings and restructurings at Canoe Health, CareMax, Prime Plastic Surgery, Atlantic Neurosurgical Specialists and Clinical Care Medical Centers as evidence that leverage alone cannot sustain clinical operations. Buyers now discount pro-forma synergies and require audited, standalone performance.
Regulatory pressure has intensified across federal and state levels. The FTC, DOJ Antitrust Division and HHS have targeted serial roll-up acquisitions, with Guideline 8 of the updated Horizontal Merger Guidelines allowing agencies to assess cumulative effects of transactions that fell below Hart-Scott-Rodino thresholds. In FTC v. U.S. Anesthesia Partners, the court dismissed Welsh, Carson, Anderson & Stowe from injunctive claims due to its minority position, but the claims against the operating company proceeded to trial. Federal regulators have also revived Section 8 of the Clayton Act to address interlocking directorates. At the state level, more than 35 states have enacted or expanded transaction review laws. The report highlights California's OHCA review with up to eight months of cost and market impact review, Oregon's 180-day notice regime with up to five years of binding conditions and a 51% physician equity requirement, Massachusetts' 215-day potential closing delay, Washington's attorney general review and New York's 30-day notice for transactions adding $25 million or more in in-state revenue. CMS disclosure rules requiring reporting of owners holding 5% or more equity are also reducing the use of offshore blocker structures.
Value-based and Medicare Advantage-focused platforms have also faced margin compression following the CMS-HCC Version 28 overhaul of risk adjustment, as underwriting assumptions of compounding annual risk-score inflation no longer hold.
Headline global healthcare private equity deal value rose sharply in 2025 to an estimated record of $191 billion. The analysis argues that this aggregate figure obscures severe bifurcation. Capital has concentrated in large-cap corporate carve-outs, upper-tier sponsor-to-sponsor recapitalisations and healthcare information technology, while mid-market provider practice roll-ups face compressed multiples, longer holding periods and liquidity constraints. Institutional sponsors are responding with stricter underwriting standards focused on market resilience, regulatory insulation and verified organic efficiency.
The analysis attributes the breakdown of the physician practice management roll-up model to several factors. Platforms relied on multiple arbitrage and debt-financed growth, with floating-rate leverage of 6.0x to 8.0x EBITDA underwritten during the zero-interest-rate period. As benchmark rates rose, debt service consumed free cash flow. Physician attrition, driven by higher throughput targets and reduced administrative support, eroded clinical capacity, while many platforms failed to integrate operations, retaining disparate electronic health records and billing practices. The report cites Chapter 11 filings and restructurings at Canoe Health, CareMax, Prime Plastic Surgery, Atlantic Neurosurgical Specialists and Clinical Care Medical Centers as evidence that leverage alone cannot sustain clinical operations. Buyers now discount pro-forma synergies and require audited, standalone performance.
Regulatory pressure has intensified across federal and state levels. The FTC, DOJ Antitrust Division and HHS have targeted serial roll-up acquisitions, with Guideline 8 of the updated Horizontal Merger Guidelines allowing agencies to assess cumulative effects of transactions that fell below Hart-Scott-Rodino thresholds. In FTC v. U.S. Anesthesia Partners, the court dismissed Welsh, Carson, Anderson & Stowe from injunctive claims due to its minority position, but the claims against the operating company proceeded to trial. Federal regulators have also revived Section 8 of the Clayton Act to address interlocking directorates. At the state level, more than 35 states have enacted or expanded transaction review laws. The report highlights California's OHCA review with up to eight months of cost and market impact review, Oregon's 180-day notice regime with up to five years of binding conditions and a 51% physician equity requirement, Massachusetts' 215-day potential closing delay, Washington's attorney general review and New York's 30-day notice for transactions adding $25 million or more in in-state revenue. CMS disclosure rules requiring reporting of owners holding 5% or more equity are also reducing the use of offshore blocker structures.
Value-based and Medicare Advantage-focused platforms have also faced margin compression following the CMS-HCC Version 28 overhaul of risk adjustment, as underwriting assumptions of compounding annual risk-score inflation no longer hold.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.